Kovitz Investment Group Partners LLC Increases Position in McKesson Corporation $MCK

Kovitz Investment Group Partners LLC lifted its holdings in McKesson Corporation (NYSE:MCK) by 38.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 48,912 shares of the company’s stock after buying an additional 13,689 shares during the quarter. Kovitz Investment Group Partners LLC’s holdings in McKesson were worth $37,807,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of MCK. Norges Bank purchased a new stake in McKesson in the second quarter worth $1,346,661,000. Alliancebernstein L.P. grew its holdings in shares of McKesson by 150.4% in the second quarter. Alliancebernstein L.P. now owns 2,268,015 shares of the company’s stock worth $1,661,956,000 after purchasing an additional 1,362,386 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of McKesson by 56.4% in the second quarter. Arrowstreet Capital Limited Partnership now owns 1,236,536 shares of the company’s stock worth $906,109,000 after purchasing an additional 446,060 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its stake in McKesson by 45.6% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 833,780 shares of the company’s stock worth $610,977,000 after buying an additional 261,296 shares during the period. Finally, Acadian Asset Management LLC lifted its holdings in McKesson by 68.0% during the 2nd quarter. Acadian Asset Management LLC now owns 636,596 shares of the company’s stock valued at $466,441,000 after buying an additional 257,670 shares in the last quarter. 85.07% of the stock is owned by institutional investors.

Insider Activity

In other McKesson news, EVP Leann B. Smith sold 190 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total transaction of $179,550.00. Following the sale, the executive vice president owned 2,989 shares in the company, valued at approximately $2,824,605. The trade was a 5.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $955.00, for a total value of $313,240.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 794 shares of company stock valued at $718,056 over the last ninety days. 0.08% of the stock is currently owned by insiders.

McKesson Stock Performance

McKesson stock opened at $947.39 on Monday. The stock has a market cap of $116.05 billion, a PE ratio of 27.25, a price-to-earnings-growth ratio of 1.53 and a beta of 0.40. The stock has a 50-day moving average of $853.65 and a two-hundred day moving average of $796.99. McKesson Corporation has a one year low of $594.34 and a one year high of $971.93.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.19 by $0.15. The firm had revenue of $106.16 billion for the quarter, compared to the consensus estimate of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, sell-side analysts predict that McKesson Corporation will post 32.77 EPS for the current fiscal year.

McKesson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 1st. Stockholders of record on Monday, March 2nd will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, March 2nd. McKesson’s payout ratio is presently 9.43%.

Analysts Set New Price Targets

A number of brokerages have commented on MCK. JPMorgan Chase & Co. upped their target price on shares of McKesson from $983.00 to $1,107.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Morgan Stanley restated an “overweight” rating and set a $966.00 price objective on shares of McKesson in a report on Thursday, January 29th. Evercore reaffirmed an “outperform” rating and set a $1,000.00 target price on shares of McKesson in a research report on Thursday, November 6th. Barclays increased their price target on McKesson from $960.00 to $1,050.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, Zacks Research downgraded McKesson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 25th. Thirteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $943.50.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.